Ambit to Use $49M from Series D VC Round to Develop Kinase Inhibitor

Nov 14, 2007

NEW YORK (GenomeWeb News) — Ambit Biosciences has landed $49.3 million in a Series D round of private-equity financing from new and existing investors, the company said today.

Ambit plans to use the funding blast to push its pipeline of small molecule kinase inhibitors, including several drug candidates it has in clinical and pre-clinical development, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Just a Few Bats

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

This Week in Nature

In Nature this week: investigation into the genetics of medulloblastoma, and more

Genomics for the Trees

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Persistent Gap

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

Main menu